Repros Therapeutics Reports Third Quarter 2016 Financial Results
THE WOODLANDS, Texas, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2016.
Financial Results
Net loss for the three month period ended September 30, 2016, was ($4.2) million or ($0.17) per share as compared to a net loss of ($6.6) million or ($0.27) per share for the same period in 2015. The net loss for the nine month period ended September 30, 2016, was ($13.3) million or ($0.55) per share as compared to a net loss of ($22.9) million or ($0.94) per share for the same period in 2015. The decreased loss for both the three and nine month periods was primarily due to decreased clinical development expenses related to the Company’s enclomiphene and Proellex product candidates, as well as decreased payroll and benefits expenses and legal expenses.
Financial Results
Net loss for the three month period ended September 30, 2016, was ($4.2) million or ($0.17) per share as compared to a net loss of ($6.6) million or ($0.27) per share for the same period in 2015. The net loss for the nine month period ended September 30, 2016, was ($13.3) million or ($0.55) per share as compared to a net loss of ($22.9) million or ($0.94) per share for the same period in 2015. The decreased loss for both the three and nine month periods was primarily due to decreased clinical development expenses related to the Company’s enclomiphene and Proellex product candidates, as well as decreased payroll and benefits expenses and legal expenses.